Literature DB >> 21475890

Cathepsin S is aberrantly overexpressed in human hepatocellular carcinoma.

Jing Xu1, Dong Li, Zhiyuan Ke, Ruiming Liu, Gunter Maubach, Lang Zhuo.   

Abstract

Several lysosomal cathepsins have been implicated in a number of diseases, from arthritis to cancer. A recent member of the cathepsin family, cathepsin S (Cat S) has been associated with several types of cancer in humans. However, to date, no report has linked Cat S to human hepatocellular carcinoma (HCC). Here, we investigated the expression of Cat S in human normal and HCC livers using immunohistochemistry and Western blot analysis. The results showed that no expression or very low levels of Cat S expression were detected in the hepatocytes of normal livers. In contrast, a significant increase in Cat S expression was detected in the cancerous hepatocytes in 34 of the total 63 HCC livers (54%; P<0.01). The Cat S-positive rate was significantly higher in the HCC nodule than in the perinodular region (P<0.01). Nevertheless, the Cat S-positive rate in the peri-HCC region was still significantly higher than that in the normal liver tissue (P<0.01). Elevated Cat S expression in HCC was positively correlated with the presence of portal vein tumor thrombus (P<0.01), extra-hepatic metastasis (P<0.05) and the degree of de-differentiation (P<0.01), but was not correlated with age, the presence of hepatitis B virus surface antigen and cirrhosis, the level of serum α-fetoprotein, the number of tumor nodules, the tumor size and the clinical stage (P>0.05). Aberrant overexpression of Cat S in the cancerous hepatocytes may be one of the key events involved in HCC tumorigenesis, invasion and metastasis.

Entities:  

Year:  2009        PMID: 21475890     DOI: 10.3892/mmr_00000161

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  15 in total

1.  Long-term endurance training increases serum cathepsin S levels in healthy female subjects.

Authors:  M Sponder; C Minichsdorfer; I-A Campean; M Emich; M Fritzer-Szekeres; B Litschauer; J Strametz-Juranek
Journal:  Ir J Med Sci       Date:  2017-11-27       Impact factor: 1.568

2.  Evaluation of serum levels of cathepsin S among colorectal cancer patients.

Authors:  Koroush Ghanadi; Saber Ashorzadeh; Asghar Aliyepoor; Khatereh Anbari
Journal:  Ann Med Surg (Lond)       Date:  2022-05-24

3.  Cathepsin S silencing induces apoptosis of human hepatocellular carcinoma cells.

Authors:  Xuedi Wang; Li Xiong; Guotang Yu; Dongdong Li; Tao Peng; Daqing Luo; Jing Xu
Journal:  Am J Transl Res       Date:  2015-01-19       Impact factor: 4.060

4.  The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study.

Authors:  J A Gormley; S M Hegarty; A O'Grady; M R Stevenson; R E Burden; H L Barrett; C J Scott; J A Johnston; R H Wilson; E W Kay; P G Johnston; S A Olwill
Journal:  Br J Cancer       Date:  2011-10-11       Impact factor: 7.640

5.  Autophagy-Regulated ROS from Xanthine Oxidase Acts as an Early Effector for Triggering Late Mitochondria-Dependent Apoptosis in Cathepsin S-Targeted Tumor Cells.

Authors:  Chien-Chang Huang; Cheng-Che Lee; Hsiao-Han Lin; Mei-Chi Chen; Chun-Cheng Lin; Jang-Yang Chang
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

6.  Melittin suppresses cathepsin S-induced invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 pathway in human hepatocellular carcinoma.

Authors:  Zhi Zhang; Hanguang Zhang; Tao Peng; Dongdong Li; Jing Xu
Journal:  Oncol Lett       Date:  2015-11-23       Impact factor: 2.967

7.  Evaluating the diagnostic and prognostic value of circulating cathepsin S in gastric cancer.

Authors:  Wan-Li Liu; Dan Liu; Kai Cheng; Yi-Jun Liu; Shan Xing; Pei-Dong Chi; Xiao-Hua Liu; Ning Xue; Yan-Zhen Lai; Ling Guo; Ge Zhang
Journal:  Oncotarget       Date:  2016-05-10

8.  Inhibition of cathepsin S confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 MAPK/JNK signaling pathways.

Authors:  Ming-Ju Hsieh; Chiao-Wen Lin; Mu-Kuan Chen; Su-Yu Chien; Yu-Sheng Lo; Yi-Ching Chuang; Yi-Ting Hsi; Chia-Chieh Lin; Jui-Chieh Chen; Shun-Fa Yang
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

9.  A bioavailable cathepsin S nitrile inhibitor abrogates tumor development.

Authors:  Richard D A Wilkinson; Andrew Young; Roberta E Burden; Rich Williams; Christopher J Scott
Journal:  Mol Cancer       Date:  2016-04-21       Impact factor: 27.401

10.  Cathepsin S attenuates endosomal EGFR signalling: A mechanical rationale for the combination of cathepsin S and EGFR tyrosine kinase inhibitors.

Authors:  Chien-Chang Huang; Cheng-Che Lee; Hsiao-Han Lin; Jang-Yang Chang
Journal:  Sci Rep       Date:  2016-07-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.